lapatinib has been researched along with Carcinoma, Adenoid Cystic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agulnik, M; Chen, EX; Cohen, EE; Cohen, RB; Dancey, J; Hayes, DN; Ho, J; Hotte, S; Laurie, S; Pond, GR; Siu, LL; Tsao, MS; Vidal, L; Winquist, E | 1 |
| Laurie, SA; Licitra, L | 1 |
| Agulnik, M; Brown, S; Chen, EX; Cohen, EW; Cohen, RB; Dancey, JE; Daneshmand, M; Hayes, DN; Ho, J; Hotte, SJ; Laurie, S; Lorimer, I; Pond, GR; Siu, LL; Tsao, MS; Vokes, EE; Winquist, E | 1 |
1 review(s) available for lapatinib and Carcinoma, Adenoid Cystic
| Article | Year |
|---|---|
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
2 trial(s) available for lapatinib and Carcinoma, Adenoid Cystic
| Article | Year |
|---|---|
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Infusions, Intravenous; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Receptor, ErbB-2; Reference Values; Salivary Gland Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Disease-Free Survival; Epidermal Growth Factor; Female; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Salivary Gland Neoplasms; Treatment Outcome | 2007 |